59,60 GLP-1RAs reduce epicardial fat, which is known to play a key role in triggering atrial remodelling in obesity
Evidence appraisal was informed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines on the formulation of clinical practice recommendations [9, 10]
GLP-1 is a protein molecule that your body naturally makes that is produced inside the intestine, that decreases blood sugar and regulates your appetite
Treatment of Obesity with GLP-1RAs GLP-1RAs enhance satiety, decrease food consumption, and delay gastric emptying, while also promoting insulin secretion and suppressing glucagon release in a glucose-dependent manner.92,93 Subcutaneous administration of liraglutide (3 mg daily) and semaglutide (2.4 mg weekly) has been approved for obesity management
These tests could include ultrasound, elastography, MRI, CT, or 18FDG-PET scans
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events A 2024 Meta-analysis of 13 multiple cardiovascular outcome trials has documented that GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
